Barinthus Biotherapeutics plc provided an update on its Phase 1 trial of VTP-1000 for treating celiac disease.
The trial showed promising results in the Single Ascending Dose (SAD) portion with no serious adverse events reported.
VTP-1000 exhibited a dose-dependent pharmacological effect, indicating potential for future treatments.
Positive SAD Trial Results
VTP-1000 demonstrated tolerability and pharmacological effects in the Single Ascending Dose section of the trial.
Ongoing MAD Portion
The Multiple Ascending Dose section, including a gluten challenge, is still in progress with data expected in the latter half of 2026.
Unique Immunotherapy Approach
VTP-1000 is an investigational antigen-specific tolerance therapy utilizing the SNAP-TI platform for immune tolerance to gluten.
- The positive results from the SAD portion of the trial indicate potential for a groundbreaking treatment for celiac disease.
- VTP-1000's ability to stimulate a targeted immune response offers hope for reducing adverse effects from gluten exposure in patients.
Barinthus Bio's Phase 1 trial of VTP-1000 showcases promising results and potential advancements in celiac disease treatment. The ongoing MAD portion will provide further insights for future treatments.